Daisuke Hirasawa

Joined Chugai Pharmaceutical Co., Ltd. in April 2001 and belonged to API Synthetic Technology Department. Since 2005, he has been engaged in the introduction of new containment equipment for handling highly active substances, the formulation of operations for manufacturing, and the manufacture of drug substances for clinical trials at Fujieda Plant. Since January 2015, he has been participating in a project to establish a new manufacturing facility ‘FJ2’ for small- and mid-size drug substance in the same position.